Natera (NASDAQ:NTRA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “

A number of other equities research analysts have also recently commented on NTRA. BidaskClub raised Natera from a “strong sell” rating to a “sell” rating in a research note on Friday, December 7th. ValuEngine cut Natera from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 9th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $25.00 price objective on shares of Natera in a research note on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $27.75.

NTRA stock opened at $18.92 on Friday. The firm has a market cap of $1.03 billion, a PE ratio of -8.80 and a beta of 1.84. Natera has a twelve month low of $8.60 and a twelve month high of $29.62. The company has a quick ratio of 2.32, a current ratio of 2.44 and a debt-to-equity ratio of 1.30.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.51). The company had revenue of $67.00 million during the quarter, compared to the consensus estimate of $62.87 million. Natera had a negative return on equity of 1,214.02% and a negative net margin of 49.72%. On average, equities research analysts predict that Natera will post -1.59 earnings per share for the current fiscal year.

In other Natera news, CTO Jonathan Sheena sold 3,043 shares of the business’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $16.00, for a total value of $48,688.00. Following the completion of the transaction, the chief technology officer now directly owns 240,201 shares of the company’s stock, valued at $3,843,216. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Steven Leonard Chapman sold 3,410 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $16.00, for a total value of $54,560.00. Following the completion of the transaction, the chief operating officer now directly owns 10,299 shares of the company’s stock, valued at $164,784. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 16,838 shares of company stock valued at $263,917. 13.18% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the business. Capital Impact Advisors LLC grew its stake in Natera by 25.5% in the fourth quarter. Capital Impact Advisors LLC now owns 102,617 shares of the medical research company’s stock valued at $1,338,000 after acquiring an additional 20,834 shares during the period. Geode Capital Management LLC grew its stake in Natera by 6.1% in the fourth quarter. Geode Capital Management LLC now owns 463,029 shares of the medical research company’s stock valued at $6,463,000 after acquiring an additional 26,771 shares during the period. FMR LLC grew its stake in Natera by 57.0% in the fourth quarter. FMR LLC now owns 3,908,921 shares of the medical research company’s stock valued at $54,568,000 after acquiring an additional 1,419,390 shares during the period. Macquarie Group Ltd. grew its stake in Natera by 5.5% in the fourth quarter. Macquarie Group Ltd. now owns 2,095,447 shares of the medical research company’s stock valued at $29,252,000 after acquiring an additional 109,869 shares during the period. Finally, Legal & General Group Plc grew its stake in Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 736 shares during the period. 90.05% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Read More: Roth IRA

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.